AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The Swedish BioFINDER - Primary Care Study

Recruitingn/aAges 40 Years - anyAllSkane University Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics. The investigators will strive to recruit diverse and representative populations of patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and mild dementia. The specific aims of the study are to: 1. Improve the detection of mild cognitive impairment (MCI) and dementia in primary care. 2. Develop and evaluate cognitive tests, blood-based biomarkers and brain imaging methods that are suitable for accurate and early diagnosis of Alzheimer's disease (AD) in primary care. 3. To prospectively validate plasma AD biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in primary care. 4. Determine whether blood AD bioma

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. The patient seeks medical help because of cognitive symptoms experienced by the patient and/or informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment. 2. The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints. 3. Age โ‰ฅ40 years 4. Subjective cognitive decline, mild cognitive impairment or mild dementia Exclusion Criteria: 1. Already diagnosed dementia 2. Significant unstable systemic illness or organ failure that makes it difficult to participate. 3. Current significant alcohol or substance misuse. 4. Refusing investigation at the Memory clinic 5. Cognitive impairment with acute onset due to stroke 6. The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.
๐Ÿ’Š

What it tests

  • Plasma APS 2 score
  • Plasma p-tau217/np-tau217
  • Plasma p-tau217
  • Plasma neurofilament light (NfL)
  • Plasma Ab42/Ab40
๐Ÿ“

Where

1 site
Primary care centers in Region Skรฅne
Malmรถ, Sweden
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy